January 28, 2016 1:03pm
The iShares Nasdaq Biotechnology ETF (IBB) held at 3% after trading 5% lower, pulling the NASDAQ between negative and positive territory while …
Stem, cell and gene therapy and RegMed (SCGT&RM) equity volumes are LOW and I believe investors are dislocated by “short-termism”.
If you are not listening now, you might not hear the music, and if you don't hear the music, how can you expect to find a chair when the music stops? Subscribe … http://www.regmedinvestors.com/create-account
I say today what others won't, so you can do what others can't whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.
U.S. stocks tried for gains Thursday, helped by a jump in oil prices; The NASDAQ outperformed in midday trade, rising more than 1%. The other major averages also recovered some of their earlier gains after briefly falling into negative territory.
The mid-day NASDAQ is UP +43.18 or +0.97% to 4,510.67 and the DOW is UP +88.92 or +0.56% to 16.033.38.
The mid-day voice in the life of the stem, cell and gene therapy RegMed (SCGT & RM) sector – the advance/decline line scenario …
- Thursday, the stem, cell and gene therapy RegMed sector opened negative with an A/DL of 20/22 and 1 flat while the mid-day was also negative with an A/DL of 11/30 and 2 flats.
Dosing the sector – what a day for the 43 Patients:
- The market opened: NEGATIVE with 22 decliners, 20 advancers and 1 flat;
- 1st hour (10:30 am): NEGATIVE with 30 decliners, 11 advancers and 2 flats;
- 2nd hour (11:30 am) NEGATIVE with 27 decliners, 14 advancers and 2 flats;
- The mid-day (12:30 pm: NEGATIVE with 30 decliners, 11 advancers and 2 flats;
The stem, cell and gene therapy RegMed (SCGT&RM) sector opened negative and stayed at the mid-day (of 43 covered companies).
- The iShares Nasdaq Biotechnology ETF (IBB) dipped 2% in morning trade.
A lot of technical damage has been done over the last few weeks, and sector “participants” have their work cut out for them in delivering a message of future appreciation.
- Investors are always asking me, what’s the most difficult call you’ve ever made? I always say it’s the call I’m making at the moment. But there are many that really touch the nerves of some CEOs … so who are the canary in the coal mine?
As James Baldwin once put it, “the most dangerous creation of any society is the man who has nothing to lose.”
- I say the truth will set you free and put an ear to this door to figure out what is going on!
My fear gauge or the CBOE Volatility Index (VIX), widely considered the best gauge of fear in the market traded
- Thursday’s mid-day traded near 22;
- Wednesday traded near 23;
- Tuesday traded below 23;
- Monday traded near 24;
The “hammer and the nail” – short and not always so sweet insights from what's likely to remain a volatile climate:
- Applied Genetic Technologies (AGTC -$0.19 or -1.26% to $14.98) depreciation is decreasing but, following its norm of falling post a few up and down days. A bottom forming, revenue recognition from Biogen (BIIB) deal will help Q2/16;
- Athersys (ATHX +$0.04 or +3.51% to $1.18) will this equity ever reward as its history of failures inhibits real appreciation;
- AxoGen (AXGN +$0.04 or +0.48% to $4.80) floats like a butterfly and regains some height;
- BioLife Solutions (BLFS +$0.05 or +2.70% to 41.90) jives and dives trying to get out of the hive;
- BioTime (NYSEMKT: BTX +$0.05 or +2.12% to $2.41) a non-deal roadshow sharpens the trade pencil but, still needs to define the interlocking relationships of its subsidiaries to future appreciation;
- bluebird bio (BLUE -$2.03 or -4.77 to $40.50) the pain is so real after the past months;
- Caladrius Bioscience (CLBS +$0.008 or -1.49% to $0.57) shouldn’t get any respect until CEO Mazzo realizes he has lost control of his shareholders as if he ever had it;
- Cytori (CYTX +$0.005 or +2.78% to $0.185) needs to reverse and balance out its listing as a good trial advances after all the issues;
- Capricor (CAPR +$0.03 or +1.29% to $2.36) March of ’15, the shares were priced at $10.25 – enough said;
- Cellectis (CLLS -$0.65 or +2.69% to $22.45) off-the-shelf T-cell therapy has been overlooked which helped an 11-month-old girl achieve a complete remission - oversold;
- Harvard Apparatus RT (HART +$0.07 or +4.32% to $1.68) what’s new post the 11/12/16 announcement of “significant” results which included evidence of complete esophageal tissue regeneration having conducted animal research on its 2nd Generation (Gen2) bioengineered implant platform (?);
- Fate Therapeutics (FATE -$0.07 or -3.18% to $2.12) is feeling the fickle slice of trading fingers. Still a favorite;
- Juno Therapeutics (JUNO -$0.85 or -2.46% to $28.58) shares are down based on the publication of the allogenic T-cell therapy study by the NIH in the current issue of the Journal of Clinical Oncology;
- Kite Pharma (KITE - $0.58 or -0.76% to $47.99) shares are down based on the publication of the allogenic T-cell therapy study at the National Institutes of Health in the current issue of the Journal of Clinical Oncology;
- Ocata therapeutic (OCAT -$0.01 or -0.12%) is still caught in the dilemma of being acquired or not – CEO Wooten shouldn’t have ignored his shareholders;
- Pluristem (PSTI -$0.023 or -2.71% to $0.835) always caught on the wrong side of communication;
- Verastem (VSTM +$0.00 to $1.33 still cash heavy per share and a trading vehicle;
Review the intricacies of correlation and causation!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.